Announcement on Subsidiary Companies Participating in the Fourth Batch of National Drug Centralized Procurement to be Bwon
Release time:
2021-05-20
Securities Abbreviations: Jianfeng Group Securities Code: 600668 No.: Lin 2021-003
Zhejiang Jianfeng Group Co., Ltd.
Announcement
on Subsidiaries Participating in the Fourth Batch of National Centralized Drug Procurement, and assume individual and joint responsibility for the truthfulness, accuracy and completeness of its contents.
On February 3, 2021 , Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Group" or "the Company"), a holding subsidiary of Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), participated in the fourth batch of national centralized drug procurement bids organized by the State Organization for Centralized Drug Procurement and Use Joint Procurement Office (hereinafter referred to as "Joint Procurement Office"), peak Pharmaceutical's Olopatadine Hydrochloride Eye Drops is proposed to win the bid for this centralized procurement. The relevant information is hereby announced as follows:
Basic Situation of 1. Proposed Winning Products
Proposed Winning Products |
Specifications |
Indications |
Proposed Winning Price |
Proposed Winning Quantity |
Provinces |
Olopatadine Hydrochloride Eye Drops |
5ml:5mg (0.1%) |
is suitable for treating signs and symptoms of allergic conjunctivitis |
19.9 yuan/ box |
36.23 box |
Shanghai, Zhejiang, Guangdong, Sichuan, Henan, Liaoning, Hubei, Chongqing, Hunan, Shaanxi, Anhui, Hainan, Xinjiang (including bingtuan), Jiangxi, Qinghai, Tibet |
the bid price and the bid quantity of the above varieties are subject to the final data released by the joint procurement office. According to the relevant winning rules, the bid period for this bid is 1 year.
The impact of 2.'s proposed winning the bid on the company
Jianfeng Pharmaceutical's proposed winning product Olopatadine Hydrochloride Eye Drops obtained the approval of State Drug Administration and issued Drug Registration Approval Document in 4 in 2019 . The market sales volume of was relatively small before , the sales revenue of this product in 2019 and 2020 1-9 September are 5.65 .01 million yuan and 97.74 .03 million yuan respectively, accounting for 2019 annual operating revenue 354 respectively, 753.76 .07 million yuan of 0.0016% and 2020 1-9 March operating income 224,065.44 .15 million yuan of 0.04% .
This centralized procurement is the fourth batch of centralized drug procurement organized by the state. During the procurement cycle, medical institutions will give priority to the drugs selected in this centralized drug procurement and ensure the completion of the agreed procurement volume. The price of the products to be selected this time has decreased to a certain extent compared with the original price. If the company subsequently signs a purchase contract and implements it, it will help expand the sales scale of the product, increase market share, and enhance the company's brand influence, which has a positive impact.3. Risk Alert
At present, the company has signed the "Memorandum of National Drug Centralized Procurement of Selected Varieties" with the Joint Procurement Office. There is still uncertainty about the follow-up matters such as the signing of the purchase agreement for the above products and the impact on the company's future performance. The company will pay close attention to the progress of the matter and timely discharge of information disclosure obligations, so that the majority of investors cautious decision-making, pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
February 5, 2001
More information
On the afternoon of June 9, Peak Cable Company organized all employees to learn fire fighting knowledge and conducted fire fighting and emergency escape drills. Since June, the subordinate enterprises of the company have organized training, learning and drills related to production safety according to their own characteristics and combined with the actual work. Safety production month series of activities carried out in an orderly manner.
2022
06-13
Spike Postdoctoral Research Papers on International Frontier Journals
Recently, good news came from the postdoctoral workstation of Jianfeng Pharmaceutical. Under the guidance of workstation mentor Jiang Xiaomeng, associate researcher Yang Xiaoxiao has made new progress in the treatment of alcoholic liver disease. The relevant research results "Roxadustat, a hypoxia-inducible factor 1a activator, attenuates both long- and short-term alcohol induced alcoholic liver disease" were published in the internationally renowned academic journal "Frontiers in Pharmacology. This journal is a frontier journal in the field of international pharmacy, mainly publishing academic papers and information on basic and clinical pharmacology, medicinal chemistry, pharmacology and toxicology.
2022
06-01
Daye Peak QC Achievements Won the Third Prize of Huangshi City
On May 7, Huangshi City Quality Strong City Working Committee organized a 2022 QC Results Conference. The QC project of "Technical Transformation of Ore Limestone Batching System" of Daye Peak Cement Company won the third prize.
2022
06-01
On April 28, Dalian Commodity Exchange held an online working meeting to announce the results of the 2021 excellent delivery warehouse and delivery warehouse excellent futures personnel selection, peak international trading company won the 2021 "excellent designated delivery warehouse" title, futures commissioner Ruan Weihang won the "excellent futures personnel" title.
2022
06-01
Cranberry extract combination identification detection method won the invention patent
After cranberry extract products were included in the "Zhejiang Province Key High-tech Product Development Project Plan" in 2021, Jianfeng Health Technology Company recently obtained an invention patent for the identification and detection method of cranberry extract. This new combined identification and detection method developed by Jianfeng Health identifies whether catechin or procyanidin B2 is added in cranberry extract by thin layer analysis, and then detects the unique A- type procyanidin and its chromatographic distribution in cranberry extract by high performance liquid chromatography, so as to improve the accuracy of product judgment. The identification method has the characteristics of accurate results and short detection time, which is of great significance to standardize the cranberry extract market and promote the healthy development of the industry, and has been unanimously recognized by peers.
2022
05-20
Daye Peak Manufacturing Department Won the Title of "Worker Pioneer" in Hubei Province
A few days ago, the manufacturing department of Daye Peak Cement Company was awarded the title of "Worker Pioneer" by the Hubei Provincial Federation of Trade Unions. Daye Jianfeng Manufacturing Department not only continued to actively explore and achieved good results in energy saving and consumption reduction, technological transformation, product quality process control, and economic responsibility system to guide management, but also improved Daye Jianfeng's overall operation level and won Huangshi City The seventh "Mayor Quality Award" created conditions and was fully affirmed by government departments at all levels.
2022
05-20
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page